4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-20-031293
Chief Executive Officer sold 15,000 shares at an average $65.25 ($978,683)
- Chief Executive Officer acquired 15,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2020-05-19 | Option exercise | +4,307 | $1.81 | $7,796 | 175,833 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-05-19 | Sale | −4,307 | $65.16 | $280,644 | 171,526 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-05-20 | Option exercise | +10,693 | $1.81 | $19,354 | 182,219 | D |
| Kulkarni Samarth Chief Executive Officer | 2020-05-20 | Sale | −10,693 | $65.28 | $698,039 | 171,526 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2020-05-19 | Option exercise · Stock Option (Right to Buy) | −4,307 | 190,751 | D | ||
| Kulkarni Samarth Chief Executive Officer | 2020-05-20 | Option exercise · Stock Option (Right to Buy) | −10,693 | 180,058 | D | ||
| Open-market sales · 15,000 sh · avg $65.25 · $978,683 | |||||||
Loading xslF345X03/doc4.xml…